VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be readily adapted to target a wide range of cancer-related antigens.
| Building | C2 |
|---|---|
| Industry | Biotech |
| Employees | 4 |
| Founding year | 2008 |
Home 
About us 
Offer 
News 
Financial support for start-ups in Basel 
Media 
Contact